Summary
1. Potency varies widely between batches; always allergy-test with a tiny match-head amount (<0.5 mg). 2. AKB-57 is active in the low-milligram range; weighing with a 0.001 g scale or volumetric dosing in PG/VG is essential. 3. Severe adverse events reported with other indazole carboxylate/carboxamide SCRAs include seizures, acute kidney injury and psychosis; similar risks should be presumed for AKB-57. 4. AKB-57 contains an ester linkage (unlike the amide in AKB48), leading to rapid ester hydrolysis as the primary metabolic pathway.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset | After Effects |
|---|---|---|---|---|
| Smoked | 0-2 min | 5-30 min | 30-90 min | 4-6 hrs |
| Oral | 30-90 min | 1-2 hrs | 30-90 min | 4-6 hrs |
Tolerance
Build-up
develops over weeks of regular use via CB1 receptor downregulation
Reset
2–4 weeks for most users; heavy users may need longer
Effects
Positive
- Stimulation
Negative
- Tachycardia then bradycardia
- Dry mouth
- Nausea/vomiting
- Nausea
- Increased heart rate
- Potent mental sedation
- Motor incoordination
- Red eyes
- Sedation
Positive
- Euphoria
- Conceptual thinking
Negative
- Short-term memory suppression
- Paranoia/anxiety/panic
- Afterglow dysphoria or irritability
- Anxiety
- Memory suppression
- Confusion
- Rapid intoxication
- Time distortion
Positive
- Tracers
- Color enhancement
- Tactile enhancement
- Increased music appreciation
- Enhanced tactile sensation
- Pattern recognition enhancement
Negative
- Closed-eye imagery at higher doses
- Dulled perception
- Drifting
- Auditory distortion